Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $5.5552W HIGH $29.27
Volume
179.39 K
Value Traded
2.57 M
Short % Float
11.16%
-8.17%Week
-11.63%1 Month
+9.7%3 Month
+144.89%6 Month
+162.03%5 Year
+162.03%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
657.13 M
EPS (TTM)
-0.85
P/E Ratio
-
Ent. Value
634.97 M
Total Shares
32.64 M
Float Shares
21.17 M
Insiders
35.16%
Institutions
33.18%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
NVCT Catalyst Timeline
Dated clinical, regulatory and corporate events for Nuvectis Pharma, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Nuvectis Pharma, Inc.
223Total events
8Upcoming
29Tier-1 (high impact)
2021 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Breakthrough Therapy DesignationNXP200Designation
NXP200 granted Breakthrough Therapy Designation in China for BRAF V600-mutant high-grade glioma
BRAF V600-mutant, recurrent or progressive, high-grade gliomasource ↗
▲Partnership / LicenseNXP100Corporate
Completed in-licensing of ex-China rights to NXP100 from Haisco
▲Partnership / LicenseNXP200Corporate
Completed in-licensing of ex-China rights to NXP200 from Haisco
▲NMPA NDA ApprovalciprocopanApprovedEx-US Regulatory
Ciprocopan (NXP100) receives NMPA marketing approval in China for treatment-naive PNH
Paroxysmal Nocturnal Hemoglobinuria (PNH) previously untreated with Complement inhibitorssource ↗
◆Topline ReadoutNXP900Clinical Data
Preliminary data readout from NXP900 Phase 1b study expected in summer 2026
oncologysource ↗
▲FDA ApprovalciprocopanApprovedFDA Decision
Ciprocopan approved in China for PNH
PNH Previously Untreated with Complement Inhibitorssource ↗
●Trial InitiationNXP900Trial
Initiation of NXP900 + lorlatinib combination study expected in 3Q2026
NSCLC ALK+source ↗
▼Equity OfferingCorporate
Pricing of $100 million public offering of common stock at $20.00 per share
▲Partnership / LicenseCorporate
Nuvectis in-licenses ex-China rights for NXP100 and NXP200 from Haisco
◆NMPA NDA ApprovalNXP100Ex-US Regulatory
MAA under NMPA review for NXP100 in C5 inhibitor-failed PNH patients
Paroxysmal Nocturnal Hemoglobinuria (PNH)source ↗
◆Trial InitiationNXP100Trial
Phase 3 trial ongoing in IgAN
Immunoglobulin A Nephropathy (IgAN)source ↗
▲Partnership / LicenseciprocopanApprovedCorporate
Exclusive license agreement with Haisco for ciprocopan outside Greater China, India and certain Southeast Asia countries
▲Partnership / LicenseNXP200Corporate
Nuvectis in-licensed exclusive worldwide ex-Greater China rights to NXP200 from Haisco
◆Oral PresentationPresentation
Nuvectis management to present at H.C. Wainwright 4th Annual BioConnect Investor Conference
◆Enrollment UpdateNXP900Trial
NXP900 Phase 1b clinical program continues to enroll patients at select sites in the US
oncologysource ↗
◆Poster PresentationNXP900Presentation
Resistance to SFK inhibitor NXP900 in cholangiocarcinoma characterized by IL13RA2-AKT signaling
cholangiocarcinomasource ↗
◆Poster PresentationNXP900Presentation
Targeting MDSCs to restore antitumor immunity in NSCLC via SRC family kinase inhibition with NXP900
NSCLCsource ↗
◆Poster PresentationNXP900Presentation
Preclinical data presented at AACR 2026 supporting NXP900 in combination with sotorasib
non-small cell lung cancer (NSCLC)source ↗
◆Enrollment UpdateNXP900Trial
Combination study with osimertinib enrolling patients
EGFR-mutated non-small cell lung cancersource ↗
▲Partnership / LicenseNXP100Corporate
In-licensed ex-China rights to NXP100 and NXP200 from Haisco
▲Trial InitiationNXP900Trial
Initiation of Phase 1b study of NXP900 in combination with osimertinib in patients with EGFRmut+NSCLC
EGFRmut+NSCLCsource ↗
◆Oral PresentationNXP900Presentation
Virtual Key Opinion Leader Meeting to discuss NXP900 Phase 1b program
advanced solid tumorssource ↗
◆Poster PresentationNXP900Presentation
NXP900 Inhibits Tumor Growth in FAT1-mutated Xenograft Models poster at 2025 AACR-NCI-EORTC
oncologysource ↗
◆Poster PresentationNXP900Presentation
Poster presentation on NXP900 inhibiting tumor growth in FAT1 mutated xenograft models at AACR-NCI-EORTC 2025
oncologysource ↗
◆Trial InitiationNXP900Trial
Expected upcoming initiation of combination component of Phase 1b
oncologysource ↗
◆Trial InitiationNXP900Trial
Start of Phase 1b program for NXP900
advanced and treatment-resistant cancerssource ↗
◆Oral PresentationPresentation
Nuvectis corporate presentation at H.C. Wainwright Global Investment Conference
◆Trial InitiationNXP900Trial
NXP900 Phase 1b program initiation expected imminently
advanced solid tumorssource ↗
◆Trial InitiationNXP900Trial
Initiation of NXP900 Phase 1b study expected in coming weeks
non-small cell lung cancer (NSCLC)source ↗
▼Equity OfferingCorporate
ATM facility share acquisition by healthcare specialized institutional investor in July 2025
◆Full ResultsNXP800Clinical Data
Final clinical data update from Phase 1b study of NXP800
recurrent, platinum resistant, ARID1a-mutated ovarian cancersource ↗
▼Program DiscontinuationNXP800Corporate
Discontinuation of NXP800 development in ovarian cancer
recurrent, platinum resistant, ARID1a-mutated ovarian cancersource ↗
▲Trial CompletionNXP900Trial
Completion of NXP900 Phase 1a dose escalation study
advanced solid tumorssource ↗
▲Trial CompletionNXP900Trial
Successful completion of DDI study in healthy volunteers
healthy volunteerssource ↗
◆Trial InitiationNXP900Trial
Phase 1b program set to begin in the coming weeks
advanced cancerssource ↗
●Milestone PaymentNXP900Corporate
One-time $2.0 million milestone achievement expense for NXP900
Past FDA Catalysts and PDUFA Decisions
How NVCT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-04-21 | NXP900 | Phase 1b data readout | Phase 1b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D34 / 100
Pipeline Score
$138M
Pipeline Value
Overvalued
Valuation Signal
1
Drugs Scored
0.2x
rNPV / MCap
Top 57%
Micro Cap(rank 375 of 658)
Percentile Rank
Nuvectis Pharma, Inc. faces pipeline headwinds (34/100), with $526M risk-adjusted pipeline value, led by NXP900 in EGFR Mutation Positive Non-small Cell Lung Cancer (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NXP900 Small moleculeNCT07315113 | EGFR Mutation Positive Non-small Cell Lung Cancer | Phase 1 | RECRUITING | 18 | Jun 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every NVCT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| NXP900 | Phase 1a | 2025-10-27 | favorable safety profile; significant pharmacodynamic responses; deep and sustained pharmacodynamic response in clinically relevant dosesRead More | Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Mosseri Marlio Charles10% Owner | Buy | 50,000 3,186,576 held | $18.32 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NVCT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 1.3 % | 28.50 M | 1.55 M |
NVCT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NVCT ranks across every disease it competes in
Competitive Position is a premium feature
See how NVCT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNVCT News
NVCTNuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
Nuvectis Pharma announced that its drug NXP200 has been granted Breakthrough Therapy Designation by China's Center for Drug Evaluation for treating BRAF V600-mutant high-grade glioma. NXP200 is a novel BRAF inhibitor designed to avoid the paradoxical activation seen with earlier therapies. The company plans to submit an Investigational New Drug application in the U.S. by the end of 2026.
Read more →NVCTNuvectis Pharma To Participate in Upcoming Investor Conferences
Nuvectis Pharma, Inc. announced its participation in two upcoming investor conferences, including the Cantor Global Healthcare Conference and the H.C. Wainwright Annual Global Investment Conference. The company focuses on developing therapies for complement-related conditions and oncology, with its lead drug candidate, ciprocopan, recently approved in China. Nuvectis aims to provide innovative treatment options for patients requiring lifelong therapy.
Read more →NVCT▼ -6.9%on this news
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
Nuvectis Pharma reported its Q2 2026 financial results, highlighting significant advancements, including the approval of ciprocopan in China for treating PNH. The company successfully raised $115 million through a follow-on offering, extending its cash runway into 2029. Nuvectis is now focused on advancing ciprocopan towards U.S. marketing application and expanding its oncology pipeline.
Read more →NVCTCorrection: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Nuvectis Pharma has received marketing approval for ciprocopan (NXP100) in China, marking it as the first once-daily oral Complement Factor B inhibitor for Paroxysmal Nocturnal Hemoglobinuria (PNH) patients who have not previously received complement inhibitors. The approval is supported by a successful Phase 3 study demonstrating ciprocopan's superiority over eculizumab. The company anticipates that ciprocopan will capture significant market share in the PNH sector and may also be effective for other complement-mediated diseases.
Read more →NVCTCiprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Nuvectis Pharma's ciprocopan (NXP100) has received marketing approval in China for treating Paroxysmal Nocturnal Hemoglobinuria (PNH) in patients previously untreated with complement inhibitors. This marks the first global approval for a once-daily oral Complement Factor B inhibitor. The approval is supported by positive Phase 3 trial results demonstrating ciprocopan's superiority over eculizumab.
Read more →NVCT▼ -35.5%on this news
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
Nuvectis Pharma has announced the pricing of its public offering, selling 5 million shares at $20 each, aiming to raise $100 million. The proceeds will support the development of its drug candidates NXP100, NXP200, and NXP900. The offering is set to close around July 1, 2026, pending customary conditions.
Read more →NVCT▼ -35.5%on this newsshared move
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
Nuvectis Pharma has announced a public offering of its common stock to support its development programs, including NXP100, NXP200, and NXP900. The offering will be managed by Cantor and includes a 30-day option for underwriters to purchase additional shares. The company aims to use the proceeds for various corporate purposes, although market conditions may affect the offering's completion.
Read more →NVCT▲ +19.6%on this news· ran to +102% by day 3
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
Nuvectis Pharma has entered a license agreement with Haisco Pharmaceutical Group for exclusive ex-China rights to two clinical-stage compounds: NXP100, a complement Factor B inhibitor, and NXP200, a paradox-breaker BRAF inhibitor. This strategic expansion aims to enhance Nuvectis's pipeline in complement-mediated diseases and oncology. Both compounds are in late-stage development, with significant market potential.
Read more →NVCTNuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Nuvectis Pharma, Inc. will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. CEO Ron Bentsur will present the company's innovative oncology treatments, including the clinical-stage drug candidate NXP900. The presentation will be available via webcast, highlighting Nuvectis' commitment to addressing unmet medical needs in cancer care.
Read more →NVCT▲ +9.2%on this news· ran to +31% by day 3
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights
Nuvectis Pharma reported its Q1 2026 financial results, highlighting the ongoing enrollment in the NXP900 Phase 1b clinical program. The company presented preclinical data at the AACR Annual Meeting, demonstrating the efficacy of NXP900 in combination with sotorasib for treating non-small cell lung cancer. Despite a rise in net loss and reduced cash reserves, Nuvectis remains focused on achieving key clinical milestones.
Read more →NVCTNuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
Nuvectis Pharma has announced that it will present its drug candidate NXP900 at the 2026 American Association for Cancer Research Meeting in San Diego. NXP900 is an oral small molecule inhibitor targeting SRC Family of Kinases, which has completed a Phase 1a study and initiated Phase 1b. This presentation highlights the company's commitment to developing innovative oncology treatments.
Read more →NVCTNuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
Nuvectis Pharma, Inc. reported its 2025 financial results, highlighting progress in the NXP900 development program. The company anticipates multiple data readouts in 2026 from its ongoing Phase 1b studies. Despite a net loss increase, Nuvectis maintains a strong cash position, expected to support its operations through 2027.
Read more →NVCTNuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
Nuvectis Pharma has announced the initiation of a Phase 1b study for NXP900 in combination with osimertinib for patients with EGFRmut+NSCLC. This study follows a successful Phase 1a dose escalation and aims to explore the safety and efficacy of the combination therapy. Eligible patients include those who have previously responded to osimertinib. The company anticipates multiple data readouts in 2026.
Read more →NVCTNuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
Nuvectis Pharma will host a virtual Key Opinion Leader Meeting on December 2, 2025, to discuss the NXP900 Phase 1b program for advanced solid tumors, including its combination with osimertinib for non-small cell lung cancer. The event will feature expert discussions on preclinical and clinical data, followed by a Q&A session. NXP900 is a selective SRC/YRS1 kinase inhibitor currently undergoing clinical trials.
Read more →NVCT▼ -7.5%on this news
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
Nuvectis Pharma, Inc. reported its third quarter 2025 financial results, highlighting a focus on advancing the Phase 1b program for NXP900. The company noted an increase in cash reserves to $35.4 million, but also reported a net loss of $7.5 million, attributed to milestone expenses and clinical study costs. Despite the losses, the emerging clinical profile of NXP900 is promising, with ongoing studies aimed at showcasing its therapeutic potential.
Read more →NVCT▼ -7.5%on this newsshared move
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
Nuvectis Pharma, Inc. reported its Q3 2025 financial results, highlighting advancements in its Phase 1b program for NXP900. The company has seen a significant increase in cash reserves, now totaling $35.4 million. However, it also reported a net loss of $7.5 million, influenced by milestone expenses and increased operational costs.
Read more →NVCT▲ +5.6%on this news
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Nuvectis Pharma presented highlights for NXP900 at the 2025 AACR-NCI-EORTC conference. The Phase 1a studies indicated a favorable safety profile and significant pharmacodynamic responses. The company is advancing to the Phase 1b program, focusing on biomarker patient selection. CEO Ron Bentsur expressed optimism about NXP900's potential as a leading SRC/YES1 inhibitor.
Read more →NVCTNuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Nuvectis Pharma, Inc. has announced upcoming poster presentations for its drug NXP900 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2025. The presentations will focus on clinical safety, pharmacokinetics, and the drug's effectiveness in inhibiting tumor growth in specific cancer models. Continued development of NXP900 underscores the company's commitment to addressing serious unmet medical needs in oncology.
Read more →NVCTNuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
Nuvectis Pharma has appointed Dr. Juan Sanchez to its Board of Directors. Dr. Sanchez, a seasoned biotech executive, brings over 30 years of experience, including significant roles in corporate communications and investor relations. His appointment comes as Nuvectis prepares to launch its Phase 1b program for NXP900, aimed at treating advanced cancers.
Read more →NVCTNuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
Nuvectis Pharma, a clinical-stage biopharmaceutical company, will participate in the H.C. Wainwright 27th Annual Global Investment Conference. CEO Ron Bentsur will present a corporate overview available for on-demand viewing starting September 5, 2025. The conference will include virtual one-on-one meetings from September 8-10, 2025, highlighting the company's focus on oncology treatments.
Read more →About Nuvectis Pharma, Inc.
Headquarters1 BRIDGE PLAZA, SUITE 275, FORT LEE, NJ, 07024
BIOPHARMAWATCH ELITE PLUS
Trade the next NVCT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime